Don M Benson

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. Benson D, Bakan C, Zhang S, Collins S, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118:6387-91 pubmed publisher
    ..These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM. ..
  2. Benson D, Cohen A, Jagannath S, Munshi N, Spitzer G, Hofmeister C, et al. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015;21:4055-61 pubmed publisher
    ..This trial was registered at www.clinicaltrials.gov (reference: NCT01217203). ..
  3. Benson D, Panzner K, Hamadani M, Hofmeister C, Bakan C, Smith M, et al. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma. 2010;51:243-51 pubmed publisher
    ..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies. ..